Phocas Financial Corp. Buys New Position in iShares Biotechnology ETF (NASDAQ:IBB)

Phocas Financial Corp. bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 430 shares of the financial services provider’s stock, valued at approximately $56,000.

Several other hedge funds also recently added to or reduced their stakes in IBB. Goldman Sachs Group Inc. grew its stake in iShares Biotechnology ETF by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock valued at $204,332,000 after purchasing an additional 521,820 shares during the last quarter. Gradient Investments LLC grew its stake in iShares Biotechnology ETF by 133,026.2% during the 3rd quarter. Gradient Investments LLC now owns 274,240 shares of the financial services provider’s stock valued at $32,075,000 after purchasing an additional 274,034 shares during the last quarter. Barclays PLC grew its stake in iShares Biotechnology ETF by 205.0% during the 3rd quarter. Barclays PLC now owns 391,633 shares of the financial services provider’s stock valued at $45,806,000 after purchasing an additional 263,247 shares during the last quarter. Itau Unibanco Holding S.A. grew its stake in iShares Biotechnology ETF by 685.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 243,605 shares of the financial services provider’s stock valued at $28,492,000 after purchasing an additional 212,608 shares during the last quarter. Finally, Commerce Bank grew its stake in iShares Biotechnology ETF by 38.0% during the 3rd quarter. Commerce Bank now owns 689,006 shares of the financial services provider’s stock valued at $80,586,000 after purchasing an additional 189,847 shares during the last quarter. 58.02% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $124.50 on Friday. iShares Biotechnology ETF has a 52 week low of $104.29 and a 52 week high of $138.74. The stock’s 50-day moving average price is $131.94 and its 200-day moving average price is $128.93.

iShares Biotechnology ETF Profile

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.